Likacin

Amikacin, the active ingredient in Likacin, is an aminoglycoside antibiotic presented as an injectable solution for intramuscular and intravenous use. It treats serious infections caused by susceptible Gram‑negative bacteria in hospitalized patients and other high‑risk groups, including those with compromised immune systems. It is commonly employed in intensive care settings where rapid bactericidal activity is required.

GNH USA supplies Likacin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory adherence across markets.

Amikacin is an aminoglycoside antibiotic used to treat serious infections caused by susceptible Gram‑negative bacteria. - Severe urinary tract infections: provides bactericidal activity against resistant Gram‑negative uropathogens. - Hospital‑acquired pneumonia: treats lung infections caused by susceptible organisms in critically ill patients. - Complicated intra‑abdominal infections: offers coverage for Gram‑negative pathogens in postoperative or perforated cases. - Septicemia: eradicates bloodstream infections due to susceptible Gram‑negative bacteria. - Skin and soft‑tissue infections: used when other agents are ineffective against Gram‑negative organisms.

Amikacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nephrotoxicity: reversible increase in serum creatinine and reduced renal clearance. - Ototoxicity (high‑frequency hearing loss): transient or permanent auditory impairment. - Vestibular toxicity: dizziness or balance disturbances. - Neuromuscular blockade: muscle weakness, especially with rapid infusion. - Rash or mild skin eruption. - Fever or chills during infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention. - Permanent hearing loss: irreversible auditory damage at high cumulative doses. - Acute renal failure: rapid decline in kidney function necessitating discontinuation. - Severe neuromuscular paralysis: respiratory compromise when combined with other neuromuscular blockers. - Thrombocytopenia: marked drop in platelet count.

When using Amikacin, careful monitoring and specific precautions are essential to minimize toxicity. - Renal function monitoring: assess serum creatinine and urine output before and during therapy. - Auditory monitoring: perform baseline audiometry and repeat assessments during treatment. - Pregnancy and lactation: avoid unless benefits outweigh potential risks to the fetus or infant. - Concomitant nephrotoxic drugs: use with caution and consider dose adjustment. - Dose adjustment in renal impairment: modify dose according to creatinine clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Amikacin can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Concurrent use with other aminoglycosides: additive nephro‑ and ototoxicity. - Loop diuretics (e.g., furosemide): increased risk of renal toxicity. - Neuromuscular blocking agents (e.g., pancuronium): potentiation of neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Vancomycin: combined use may enhance nephrotoxicity. - Cephalosporins: possible antagonistic effect reducing bactericidal activity. - NSAIDs (e.g., ibuprofen): may increase risk of renal impairment.